WHY KAIROS?
Unmet Medical Need |
Drug |
How Kairos Addresses Unmet Medical Need |
Development of resistance to many, otherwise effective, cancer drugs (hormone based therapies, EGFR-based therapies, radiation, and other specific chemotherapies) |
ENV 105 |
• ENV105 inhibits CD105 (CD105 is the protein responsible for cancer drug resistance in various forms of cancer) • Currently in Phase 2 trial in prostate cancer and Phase 1 trial in lung cancer |
T cells drastically reduced by cancer
|
KROS 101 |
• KROS101 uses a novel dual mechanism to increase killer T cells and reduce suppressor T reg cells (T cells have 2 types cells: those that kill cancer cells and those that inhibit the killer T cell response) |
In autoimmune diseases, T cells are overactive against normal cells |
KROS 102 |
• KROS102 has the opposite effect of KROS101, by decreasing the number overactive T cells and increasing Treg suppressor cells |
Immunosuppression from cancer |
KROS 201 |
• KROS201 are killer T cells generated outside of the immunosuppressed body which will be delivered to cancer cells to kill cancer stem cells that drive cancer growth. • Currently cleared for IND (investigational new drug application) by FDA |
Chemotherapies are untargeted and immunosuppressive |
KROS 301 |
• By targeting the NF-kB molecular pathway, KROS 301 aims to kill tumors and inhibit the mechanism of PD-L1 expression on tumor cells (PD-L1 is a “checkpoint inhibitor” that prevents T cells from killing the cancer) |
Tumor environment is immunosuppressive from macrophages (a type of white cell that can be either anti-cancer or pro-cancer) |
KROS 401 |
• KROS401 targets pro-cancer macrophages to convert them into anti-cancer macrophages |
Development of resistance to various specific chemotherapies |
ENV 205 |
• ENV205 targets & expels mitochondrial DNA that are released by tumors which use this mechanism of resistance against specific chemotherapies |
Investment highlights
- Three ongoing clinical programs
- Phase 2 trial treating Prostate Cancer with NIH grant funding
- Phase 1 trial in treating Non-Small Cell Lung Cancer –Non-dilutive, Donor funded
- Cleared IND for Glioblastoma
- Strategic relationship with Cedars-Sinai Medical Center (ranked #2 hospital nationally in 2022-2023 US News and World Report) enhances clinical trial efficiency (costs and enrollment) and streamlines therapeutic innovation
- Initial clinical development focuses on overcoming cancer drug resistance derisked with extensive safety studies and biomarker for potential response
- Extensive therapies to reverse immune suppression in our pipeline
- Extensive IP portfolio valid until 2035 to 2040
- Our technologies target a high value, large market - targeting a fast growing $11.3 billion hormone therapy prostate cancer market, $14 billion lung cancer market, and $94 billion immunotherapy market